GCP
ANVS icon

Gill Capital Partners’s Annovis Bio ANVS Stock Holding History

Gill Capital Partners’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.4K Hold
18,579
– – 0.01% 289
2025
Q4 		$64.3K Buy
+18,579
New +$55.8K 0.02% 138

Other funds holding ANVS

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Gill Capital Partners's ANVS Position: Q1 2026 in Review

Gill Capital Partners held its Annovis Bio (ANVS) position steady in Q1 2026 at 18,579 shares worth $41.4K. The position accounts for 0.01% of the portfolio, ranked #289.

Gill Capital Partners first reported a position in ANVS in Q4 2025 and has held it in 2 quarters since. The position peaked at $64.3K in Q4 2025. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • Gill Capital Partners held 18,579 shares of Annovis Bio worth $41.4K as of Q1 2026.
  • Gill Capital Partners left its Annovis Bio share count unchanged in Q1 2026.
  • Annovis Bio made up 0.01% of Gill Capital Partners's portfolio in Q1 2026, its #289 holding.
  • Gill Capital Partners first reported a position in Annovis Bio in Q4 2025 and has held it in 2 quarters since.
  • Gill Capital Partners's Annovis Bio position peaked at $64.3K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.